Biotech with Transformative RNAi Delivery System Set for Multiple Catalysts by Year-End
Source: Streetwise Reports��(10/4/17)
With data from multiple studies due out this quarter, this biotech's RNA interference delivery platform has the potential to transform treatments for indications from cancer to ophthalmology, says Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals, Dr. Gerrit Dispersyn, RXi's Chief Development Officer, and Dr. Karen Bulock, Vice President of Research at RXi.
More >

Small-Cap Biotech Benefits from First FDA Approval of CAR-T Therapy
Source: Streetwise Reports��(9/1/17)
The first approval of a cell therapy for treatment of pediatric blood cancer prompted H. C. Wainwright to increase its price target for a UK-based biotech manufacturing one of the therapy's components.
More >

With Acquisition of Kite Pharma, Gilead Becomes a 'Major Player' in CAR-T Arena
Source: Streetwise Reports��(8/30/17)
Jason Kolbert, analyst with Maxim Group, assesses the billion-dollar transaction that would bring Kite Pharma and the earning potential of its cell therapy programs under the larger biotech's umbrella.
More >

Analyst Says Cell Therapy Company's Move Decreases Risk
Source: Streetwise Reports��(8/23/17)
A regenerative medicine company has signed on to the ThawSTAR Early Adopter Program, a move analyst Douglas Loe of Echelon Wealth Partners terms "positive logistically" to development risk. More >

'Keep a Close Eye On' This Regenerative Medicine Firm
Source: Streetwise Reports��(8/16/17)
In an update on this company's clinical cell therapy programs targeting blood cancers and osteoarthritis in the knee, Gabrielle Zhou of Maxim Group describes progress that sets the stage for "value inflection."
More >

2017 Small-Cap Biotech Watchlist Update: Up 21% at the End of Q2/17
Source: Streetwise Reports��(7/13/17)
If an investor had purchased an equal dollar amount of each company on The Life Sciences Report's 2017 Small-Cap Biotech Watchlist at the beginning of the year, that portfolio would show a gain of about 21% as of July. This is primarily due to the performance of a handful of companies that have been moving their assets farther down the development pipeline, according to the analysts who follow them. More >

RXi Pharmaceuticals Expands Collaboration with Norwegian Cancer Firm; Gears Up for 2017 Milestones
Source: The Life Sciences Report��(6/7/17)
The potential of RXi Pharmaceuticals' sd-rxRNA technology in the development of cancer immunotherapies has resulted in an extension of its research collaboration with Oslo-based PCI Biotech and captured the attention of two analysts. More >

Mesoblast Heart Failure Trial Delivers Positive Interim Results
Source: The Life Sciences Report��(5/3/17)
Mesoblast Ltd., an Australia-based regenerative medicine company currently in a Phase 3 clinical trial in chronic heart failure, has received successful interim data, which prompted the Maxim Group to comment favorably on the study's design and progress. More >

2017 Small-Cap Biotech Watchlist Update: Holding Steady in a Volatile Market
Source: The Life Sciences Report��(4/19/17)
The Small-Cap Biotech Watchlist, composed of 20 companies targeting a range of indications including blood cancers and solid tumors, irritable bowel disease and orphan diseases, has posted a modest gain since the first of the year.
More >

String of Positive Trial Results Boosts RepliCel's Profile
Source: The Life Sciences Report��(4/12/17)
Positive results from RepliCel's Phase 1 trial for the treatment of aging and sun-damaged skin follow the release in the past few weeks of positive data from trials for chronic tendon problems and for hair loss. More >

RXi Pharmaceuticals Receives Japanese Patent for RNAi Platform
Source: The Life Sciences Report��(4/12/17)
With the granting of a new patent in Japan for its lead compound, RXI-109, RXI Pharmaceuticals has strengthened its reach in Asian markets and enhanced the protections surrounding its proprietary RNAi platform. More >

RepliCel's Phase 1 Trial for Hair Loss Completed Successfully
Source: The Life Sciences Report��(3/16/17)
RepliCel's successful conclusion of its Phase 1 trial for hair loss sets it up for the next steps in the drug's development. More >

Regeneus Hits the Fast Track with Major Japanese Partnership
Source: The Life Sciences Report��(2/8/17)
Regeneus, an Australian regenerative medicine company, has entered into a collaboration with a major Japanese firm to manufacture its stem cell therapy Progenza, a move that may accelerate approval and that has a pair of analysts optimistic about the company's future. More >

Companies Flocking to Japan for Biotech Deals
Source: Colin Lee Novick for The Life Sciences Report��(2/1/17)
For the last two years, Japan has been at the forefront of accelerated approval for regenerative medicine products and has seen lots of licensing and contract manufacturing deals and M&A activity. Tokyo-based Colin Lee Novick, managing director of CJ PARTNERS, surveys the landscape, discussing recent tie-ups, the effects of the recently passed 21st Century Cures Act in the U.S., and what may lie ahead. More >

2017 Small-Cap Biotech Watchlist: Takeaways for Investors
Source: The Life Sciences Report��(1/18/17)
Why should investors keep an eye on these twenty small-cap biotechs in 2017? The analysts who made the selections for The Life Sciences Report's 2017 Small-Cap Biotech Watchlist laid out their rationales at the Watchlist's launch at the Biotech Showcase in San Francisco on Jan. 11. More >

Time to Go Long on BrainStorm Cell Therapeutics?
Source: Jason Napodano CFA of BioNap Inc. for The Life Sciences Report��(1/16/17)
Jason Napodano of BioNap Consulting takes an in-depth look at BrainStorm Cell Therapeutics, including the science, the Phase 2 data and the potential valuation of the company developing adult stem cell-based therapies for neurodegenerative diseases. More >

19 Companies Selected for the 2017 Small-Cap Biotech Watchlist
Source: The Life Sciences Report��(1/3/17)
Now in its fifth year, the 2017 Life Sciences Report Biotech Watchlist includes nineteen small-cap biotech companies selected by top analysts in the field, and will be presented at the Biotech Showcase in San Francisco in January. More >

VistaGen Licenses Stem Cell Technology to New Firm Backed by Big Pharma
Source: The Life Sciences Report��(12/21/16)
VistaGen Therapeutics has granted an exclusive sublicense for its stem cell technologies to BlueRock Therapeutics, a new biotech backed by pharma heavyweight Bayer AG and venture capital firm Versant Ventures of San Francisco. More >

Stock-Moving Catalysts Anticipated for Regeneus in Q4/16
Source: The Life Sciences Report��(9/28/16)
Australian regenerative medicine company Regeneus Ltd. has a handful of stock-moving Q4/16 catalysts on the calendar, among them a potential licensing agreement for its mesenchymal stem cell technology in Japan. More >

Regeneus Secures Government Funding for R&D
Source: The Life Sciences Report��(9/14/16)
The Australian government has bolstered Regeneus, a regenerative medicine company targeting cancer, osteoarthritis and other musculoskeletal conditions, with $2.73 million in funding. More >

Investment in Cell and Gene Therapies Ramps Up
Source: George S. Mack of The Life Sciences Report��(6/8/16)
After decades of disappointment, cell therapies and gene therapies are finally seeing light at the end of the tunnel. Investors, investigators, clinicians, and patients with serious unmet needs are watching pivotal trials move into the home stretch. Yes. . .pivotal data are actually on the way. More >

Advantage: Australia. Biotechs Surge Ahead in Regenerative Medicine and Immuno-Oncology
Source: George S. Mack of The Life Sciences Report��(5/11/16)
Biotech and medtech startups are not confined to the U.S. and Europe. Unmet medical needs exist all over the globe, and they create a powerful vacuum that sucks in bright minds and risk-taking capitalists. Australia is a good example: The regulatory environment supports first-in-human experimentation and entrepreneurship. Healthcare Analyst Dennis Hulme of Edison Investment Research is headquartered in Sydney, and in this interview with The Life Sciences Report, he cites a group of Australian medtech and biotech names that investors should look at very carefully. More >

What Andy Grove and Michael Milken Have Taught Us About Prostate Cancer
Source: George S. Mack of The Life Sciences Report ��(4/20/16)
Solid tumors are typically managed with surgical resection, chemotherapy, radiation and biologics, but it's the secondary tumor mass, the metastasis, that kills patients. Dr. Stuart Holden of the UCLA Institute of Urologic Oncology understands the importance of targeting metastatic disease, which is driven by different genetic factors than the primary tumor from which it arose—a fact that oncologists are just now coming to grips with. In this interview with The Life Sciences Report, Dr. Holden describes an essential target in aggressive prostate cancers, and a drug with the potential to address that target and extend the lives of thousands of men. More >

Seven Biotech Names on the Upswing: 2016 Small-Cap Biotech Watchlist Update
Source: Tracy Salcedo of The Life Sciences Report��(3/9/16)
Biotech stocks—and the stock market in general—took a dive at the beginning of 2016, headed down on macroeconomic factors such as financial instability in China. The Life Sciences Report's 2016 Small-Cap Biotech Watchlist was not immune to that movement, heading into negative territory almost from the moment the selected companies were introduced. But as the market has shown signs of rebounding, so too has the Watchlist.
More >

Embrace Low-Cap Biotech for High Gains: Eden Rahim of Next Edge Capital
Source: George S. Mack of The Life Sciences Report��(3/2/16)
Eden Rahim of Toronto-based Next Edge Capital has had his share of multibagger and grand-slam successes, and is one of the few mutual fund managers who feels comfortable investing in micro-cap biotech names side-by-side with billion-dollar biotech stocks. In this interview with The Life Sciences Report, Rahim describes a group of micro-, small- and mid-cap biotech names possessing powerful growth drivers that could perform even when the overall market is not so hot. More >